Policy & Regulation
4basebio announces Phase I cell therapy programme partnership with TriLink
28 September 2026 - Cambridge-based biotechnology company 4basebio PLC (AIM: 4BB) reported on Monday that it is to supply clinical-grade opDNA synthetic DNA for a multinational pharmaceutical company&...
Kodiak Sciences to present topline Phase 3 study results for Zenkuda and KSI-501 in wet AMD
28 September 2026 - Kodiak Sciences Inc (Nasdaq:KOD), a precommercial retina-focused biotechnology company, said on Friday that the company will report topline results from DAYBREAK, a Phase 3 study e...
IASO Bio presents first-in-human data of BCMA-targeted in vivo CAR-T cell therapy IASO206 at 2026 IMS
28 September 2026 - Chinese commercial-stage biopharmaceutical company IASO Biotechnology (IASO Bio) announced on Saturday the presentation of first-in-human (FIH) Phase 1 clinical data for IASO206, i...
Innovent expands global Phase 3 study of IBI363/TAK-928 to include non-squamous NSCLC
28 September 2026 - Chinese biopharmaceutical company Innovent Biologics Inc (HKEX:01801) announced on Sunday an expansion of the global Phase 3 MarsLight-11 trial, which is evaluating IBI363 (Takeda ...
Akeso enrols first patient in global Phase III trial of cadonilimab vs nivolumab in first-line gastric cancer
28 September 2026 - Chinese pharmaceutical company Akeso Inc (HK:9926) announced on Sunday that the first patient has been enrolled in COMPASSION-37 (AK104-311), a global, multicentre Phase III head-t...
Lundbeck to relocate US headquarters to Greater Boston
25 September 2026 - Danish biopharmaceutical company H. Lundbeck A/S (CPH: HLUN-B) on Friday announced plans to move its US headquarters from Deerfield, Illinois, to Greater Boston, Massachusetts.Lund...